Literature DB >> 21706367

Elevated content of osteopontin in plasma and tumor tissues of patients with laryngeal and hypopharyngeal carcinoma associated with metastasis and prognosis.

Yong Li1, Liang Li, Jing Ting Wang, Xuan Kan, Jian Guang Lu.   

Abstract

The aim of this study was to evaluate the usefulness of osteopontin (OPN) expression level in plasma and tumor tissues of patients with laryngeal and hypopharyngeal squamous-cell carcinoma for predicting metastasis and survival of this tumor. The OPN expression in tumor tissues was detected by immunohistochemical staining in a tissue microarray of laryngeal and hypopharyngeal carcinomas, and the OPN level in plasma was measured by ELISA. The expression levels of OPN in plasma and tumor tissues were associated with clinicopathological features and survival of laryngeal and hypopharyngeal carcinomas. Results showed that the OPN expression quantitation either in tissues or plasma was significantly correlated with differentiation and lymphatic metastasis of the laryngeal and hypopharyngeal carcinoma. Elevated OPN level of plasma and tissues was significantly associated with poor survival. In conclusion, elevated OPN level in plasma and tumor tissues was significantly associated with metastasis and survival of laryngeal and hypopharyngeal carcinomas. Elevated OPN level in plasma and tumor tissues may become a useful indicator of prognosis for laryngeal and hypopharyngeal cancers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21706367     DOI: 10.1007/s12032-011-0012-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  21 in total

1.  A novel RGD antagonist that targets both alphavbeta3 and alpha5beta1 induces apoptosis of angiogenic endothelial cells on type I collagen.

Authors:  Karen Meerovitch; Frédéric Bergeron; Lorraine Leblond; Brigitte Grouix; Cathy Poirier; Monica Bubenik; Laval Chan; Henriette Gourdeau; Terry Bowlin; Giorgio Attardo
Journal:  Vascul Pharmacol       Date:  2003-02       Impact factor: 5.773

Review 2.  The regulation and role of osteopontin in malignant transformation and cancer.

Authors:  Mohamed K El-Tanani; Frederick Charles Campbell; Vittal Kurisetty; Dachuan Jin; Mella McCann; Philip S Rudland
Journal:  Cytokine Growth Factor Rev       Date:  2006-11-17       Impact factor: 7.638

3.  Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer.

Authors:  N S Fedarko; A Jain; A Karadag; M R Van Eman; L W Fisher
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

4.  CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis.

Authors:  Y U Katagiri; J Sleeman; H Fujii; P Herrlich; H Hotta; K Tanaka; S Chikuma; H Yagita; K Okumura; M Murakami; I Saiki; A F Chambers; T Uede
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

5.  Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness.

Authors:  Angela Celetti; Domenico Testa; Stefania Staibano; Francesco Merolla; Valentina Guarino; Maria Domenica Castellone; Renata Iovine; Gelsomina Mansueto; Pasquale Somma; Gaetano De Rosa; Vieri Galli; Rosa Marina Melillo; Massimo Santoro
Journal:  Clin Cancer Res       Date:  2005-11-15       Impact factor: 12.531

6.  Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers.

Authors:  Yutaka Shimada; Go Watanabe; Junichiro Kawamura; Toshiya Soma; Michio Okabe; Tetsuo Ito; Harutaka Inoue; Masato Kondo; Yukiko Mori; Eiji Tanaka; Masayuki Imamura
Journal:  Oncology       Date:  2005-07-07       Impact factor: 2.935

7.  Osteopontin as a potential diagnostic biomarker for ovarian cancer.

Authors:  Jae-Hoon Kim; Steven J Skates; Toshimitsu Uede; Kwong-kwok Wong; John O Schorge; Colleen M Feltmate; Ross S Berkowitz; Daniel W Cramer; Samuel C Mok
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

8.  Receptor-ligand interaction between CD44 and osteopontin (Eta-1).

Authors:  G F Weber; S Ashkar; M J Glimcher; H Cantor
Journal:  Science       Date:  1996-01-26       Impact factor: 47.728

9.  Role of the alpha v-integrin subunit in cell proliferation, apoptosis and tumor metastasis of laryngeal and hypopharyngeal squamous cell carcinomas: a clinical and in vitro investigation.

Authors:  Jian Guang Lu; Ya Nan Sun; Chao Wang; De Jun Jin; Ming Liu
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-04-22       Impact factor: 2.503

10.  Prognostic value of cell proliferation markers, tumour suppressor proteins and cell adhesion molecules in primary squamous cell carcinoma of the larynx and hypopharynx.

Authors:  Ming Liu; Georges Lawson; Monique Delos; Jacques Jamart; Bernard Chatelain; Marc Remacle; Etienne Marbaix
Journal:  Eur Arch Otorhinolaryngol       Date:  2002-07-24       Impact factor: 2.503

View more
  9 in total

Review 1.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

2.  Factors contributing to lymph node occult metastasis in supraglottic laryngeal carcinoma cT2-T4 N0M0 and metastasis predictive equation.

Authors:  Hongzhi Ma; Meng Lian; Ling Feng; Pingdong Li; Lizhen Hou; Xiaohong Chen; Zhigang Huang; Jugao Fang
Journal:  Chin J Cancer Res       Date:  2014-12       Impact factor: 5.087

3.  Functional characterization of OPN in human laryngeal squamous cell carcinoma and its xenograft model in nude mice.

Authors:  Jianqiu Chen; Qi Zhou; Chunsheng Zhu; Minhui Zhu; Yongsheng Tian; Guojun Li; Xiaofeng Tao; Hongliang Zheng
Journal:  Int J Clin Exp Med       Date:  2015-01-15

4.  Association of OPN overexpression with tumor stage, differentiation, metastasis and tumor progression in human laryngeal squamous cell carcinoma.

Authors:  Jianqiu Chen; Chunsheng Zhu; Zhen He; Min Geng; Guojun Li; Xiaofeng Tao; Fenghua Zhang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

5.  Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma.

Authors:  Felicitas Strehlow; Sandra Bauer; Peter Martus; Michael Weller; Patrick Roth; Uwe Schlegel; Sabine Seidel; Carmen Scheibenbogen; Agnieszka Korfel; Stephan Kreher
Journal:  J Neurooncol       Date:  2016-06-13       Impact factor: 4.130

6.  Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin.

Authors:  Xiang-Qian Zhao; Jia-Hong Dong; Wen-Zhi Zhang; Zhe Liu
Journal:  Diagn Pathol       Date:  2011-10-13       Impact factor: 2.644

7.  Osteopontin production by TM4SF4 signaling drives a positive feedback autocrine loop with the STAT3 pathway to maintain cancer stem cell-like properties in lung cancer cells.

Authors:  Soo Im Choi; Seo Yoen Kim; Jei Ha Lee; Jung Yul Kim; Eun Wie Cho; In-Gyu Kim
Journal:  Oncotarget       Date:  2017-09-18

8.  Plasma osteopontin concentrations in patients with cutaneous melanoma.

Authors:  A Filia; F Elliott; T Wind; S Field; J Davies; K Kukalizch; J Randerson-Moor; M Harland; D T Bishop; R E Banks; J A Newton-Bishop
Journal:  Oncol Rep       Date:  2013-08-08       Impact factor: 3.906

9.  Overexpression of miRNA 4451 is Associated With a Poor Survival of Patients With Hypopharyngeal Cancer After Surgery With Postoperative Radiotherapy.

Authors:  Xinbo Xu; Heng Liu; Neil Gross; Dongmin Wei; Ye Qian; Wenming Li; Peng Wei; Guojun Li; Fenghua Zhang; Zheng Yang; Dapeng Lei; Xinliang Pan
Journal:  Transl Oncol       Date:  2018-08-10       Impact factor: 4.243

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.